

Evaluation of some coagulation profile and estimation of fibrinogen level in sudanese patients with type II diabetes mellitus

Abdelrhman AH^{1*}, Ahmed A²

¹Department of Hematology and Immunohematology, Omdurman Islamic University, Sudan.

²Head Department of Hematology and Immunohematology, Omdurman Islamic University, Sudan.

*Correspondence: Amged Hussien Abdelrhman, Department of Hematology and Immunohematology, Omdurman Islamic University, Sudan; E-mail: Amgedhussen66@gmail.com

Received date: June 17, 2020; **Accepted date:** June 25, 2020; **Published date:** July 03, 2020

Copyright: © 2020 Abdelrhman AH, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

BACKGROUND: Type II diabetes, fibrinogen levels have been demonstrated to predict the progression to overt nephropathy. Hyperfibrinogenemia, an indicator of inflammation, is also associated with the presence of endothelial dysfunction, insulin resistance, hypercoagulability, and increased blood viscosity and is a marker of unstable atherosclerotic lesions.

AIM: This study aimed to evaluation of coagulation profile and D-dimer and estimation of Serum Fibrinogen Level in Sudanese Patients with type II Diabetes Mellitus in Khartoum State.

METHODS: A questionnaire was designed to collect information about the study group, Blood sample were collected from all participants in Tri sodium citrate containers. Automated coagulometer (COATRON M1) was used to evaluate prothrombine time and activated partial thromboplastine time and measure fibrinogen level. D-dimer levels were evaluated using (ichroma™) Reader fluorescence scanning instrument an integrated Point of Care Test (POCT) system.

RESULTS: The study showed that the mean and standard of PT, APTT, INR was (17.9 ± 3.8 sec, 32.6 ± 4.1 sec, 1.1 ± 0.3 respectively), the mean of age among study group was (53 ± 14.2 years), there was significant different when correlate PT and management of disease (p. value 0.01) . the present study show insignificant correlation between PT and treatment, complication and gender (0.20 , 0.13 and 0.08) respectively while APTT there was significant difference with management ,complication and gender p. value was (0.01 , 0.03 and 0.01 respectively) .The mean \pm SD of fibrinogen level was 136 ± 20.7 ,the mean \pm SD of fibrinogen level in male was 137.4 ± 20.6 mg/dl and in female was 135.22 ± 20.9 mg/dl. The present study show the insignificant correlation among gender p-value was (0.594). The frequency of duration

of disease in group less than 5 years was (34%), in 5-10 years was (41%) and in group more than 10 years was (25%). Statistically insignificant differences between fibrinogen level and duration of disease were observed p-value (0.776), there was insignificant difference between fibrinogen level and different age group p. value (0.66). The mean of D-dimer levels is (1309.3 ± 324.1 mg/ml).

CONCLUSION: The present study show that shortened prothrombin time, activated partial thromboplastin time, shortened PT and APTT might be useful haemostatic markers in diabetic patients, especially in those at high risk for thrombotic complications. The Mean of plasma fibrinogen level in patient with type II diabetics mellitus were 136.3mg/dl, insignificant correlation with Fibrinogen levels with age, gender and duration of disease. The D. Dimer level show significant increase.

Key Words: *Coagulation profile; Fibrinogen; Type II diabetics mellitus*

INTRODUCTION

The concept of blood coagulation dates back to 1960 when Davie, Ratnoff and Macfarlane described the "waterfall" and "cascade" theories outlining the fundamental principle of cascade of pro-enzymes leading to activation of downstream enzymes [1]. Haemostasis, defined as arrest of bleeding, comes from Greek, haeme meaning blood and stasis meaning to stop [2]. Thrombohaemorrhagic balance is maintained in the body by complicated interaction between coagulation and fibrinolytic system as well as platelets and vessel wall. Usually the coagulation processes under the inhibitory control of several inhibitors that limit the clot formation, avoiding thrombus propagation. This delicate balance is interrupted whenever the pro-coagulant activity of the coagulation factors is increased, or the activity of naturally occurring inhibitors is decreased [3]. Diabetics Mellitus (DM) is a metabolic disorder characterized by chronic hyperglycemia due to disturbances of carbohydrate, fat, and protein metabolism that are associated with absolute or relative deficiencies in insulin secretion, insulin action or both (Charles, 1998). Diabetes have three main types : type one diabetes mellitus which called (IDDM) , type two diabetes mellitus which called (NIDDM)and gestational diabetes which is classified as type two diabetes mellitus. The long term affects and complications of diabetes include progressive development of the retinopathy, and neuropathy with micro vascular and macro vascular diseases. Macrovascular disorders such as atherosclerosis are recognized as a major cause of mortality in diabetic population, and are implicated in the circulatory disturbances that are seen in diabetes. The circulatory disturbances are further complicated by alteration in platelet count and activity, coagulopathy, fibrinolytic aberration, haemorrhological factors, and changes endothelial metabolism [4]. Many studies have shown that diabetes is a hypercoagulable state. Hypercoagulability results from enhanced vascular endothelial cell expression of tissue factor and Von Willebrand factor. Other factors include increased platelet adhesiveness, elevated level of procoagulant factor and decreased fibrinolytic activity [5].

MATERIAL AND METHODS

Sample collection and sample Techniques: Venous blood sample was collected using sterile plastic syringe after cleaning the venipuncture area with 70% ethanol, the blood was added to the anticoagulant at ratio of 9.1 to 0.5ml of tri sodium citrate (3.2% (0.109M) buffered

sodium citrate and gently mixed. The sample was centrifuge at 4.500 rpm for 15min to obtain Platelet Poor Plasma (PPP). The Platelet Poor Plasma (PPP) placed into plastic tube. The PT, APTT and fibrinogen level was measured using the Automated Coagulometer Analyzer (ACA). This Fibrinogen test based upon the Fibrinogen antigen-antibody reaction. D-Dimer levels were evaluated using ichroma™ Reader fluorescence scanning instrument an integrated Point Of Care Test (POCT) system .

RESULTS

In the present study the frequency of mean and standard of PT among study group (17.9) (3.8%), APTT (32.6) (4.1%), INR (1.1) (0.3%), **Table 1**. In the present study there is insignificant association between PT and treatment and gender p. value (0.193) **Table 2**, insignificant association between APTT and management, hypertension, treatment and gender was observed p. value (0.197, 0.34, 0.39, 0.21) respectively **Table 3**. In this study there is significant positive correlation between the age and PT result (p-value 0.05) **Figure 1** and significant positive correlation between the age and APTT (p-value 0.02) **Figure 2**. The result show the mean \pm SD of age among study group was (47 \pm 16.6 years), the mean \pm SD of duration of the disease was (7.6 \pm 3.1 years) and the mean \pm SD of fibrinogen level was 136 \pm 20.7, the frequency of male 50% and female 50% **Table 4**. The mean of the fibrinogen level among the study group that different between male and female ,the mean \pm SD of fibrinogen level in male was 137.4 \pm 20.6mg/dl and in female was 135.22 \pm 20.9mg/dl. The present study show the insignificant correlation among gender p-value was (0.594) **Table 5** 98% of the study show fibrinogen level than 180 mg/dl and 2% more than 180 mg/dl **Figure 3**. The frequency of duration of disease in group less than 5 years was (34%), in 5-10 years was (41%) and in group more than 10 years was (25%). Statistical insignificant differences between fibrinogen level and duration of disease were observed p-value (0.776) **Table 6**. In present study there was an increase in D-Dimer level, mean (1309.3 \pm 324.1mg/ml), (D-dimer normal values: <250mg/ml), **Table 7**. The mean of D-dimer levels in subjects with no other complications and subjects with hypertension was (2267.3 \pm 642.3 mg/ml), and showed significant statistical correlation (p-value = 0.033) **Table 8**.

Parameter	Mean	Standard
PT	17.9 Sec	3.8
APTT	32.6 Sec	4.1
INR	1.1	0.3
Age	52.7 years	14.2

TABLE 1:: Mean and Standard of PT, PTT, INR and Age.

Parameters	Treatment (Mean \pm SD)	p-value
PT (second)	17.6 \pm 3.8	0.02
APTT (second)	32.6 \pm 4.1	0.39

TABLE 2:: Comparison of PT & APTT according to treatment among study population.

Parameters	N	Minimum	Maximum	Mean	SD
Age (years)	100	16	77	47.3	16.6
Fibrinogen level (mg\dl)	100	99	189	136.3	20.7
Duration (years)	100	3	12	7.6	3.1

TABLE 3:: Descriptive statistics of study variables.

Parameters	Gender (Mean \pm SD)		p-value
	Male (n=50)	Female (n=50)	
Fibrinogen level (mg\dl)	137.4 \pm 20.6	135.22 \pm 20.9	0.594

TABLE 4:: Correlation between Fibrinogen level among gender.

Duration of disease	Frequency	Fibrinogen (Mean \pm SD)	p-value
Less than 5 years	34	137.4 \pm 22.7	0.776
5-10	41	134.6 \pm 21.5	
More than 10	25	137.8 \pm 16.9	

TABLE 5:: Comparison of fibrinogen level among duration of disease group.

Age groups	Frequency	Fibrinogen (Mean \pm SD)	p-value
Less than 20 years	8	142.6 \pm 27.1	0.667
20 – 30 years	14	136.7 \pm 226	
31 – 40 years	10	131.7 \pm 27.4	
41 – 50 years	19	137.3 \pm 20.8	
50 – 60 years	22	139.7 \pm 16.1	
61 – 70 years	22	130.3 \pm 16.9	
More than 70 years	5	142.4 \pm 25.9	

TABLE 6:: Comparison of fibrinogen level among age group.

Parameter	N	Minimum	Maximum	Mean	SD
D-dimer	100	133.9	6706.4	1517.3	373.5

TABLE 7:: Mean of D-dimer among study group.

Parameter	Population study		p-value
	No other disease (n=50)	Hypertension (n=50)	
D-dimer	2267.3 \pm 642.3	7048.5 \pm 611.1	0.033

TABLE 8:: Comparison of D-dimer levels with no other complications and with hypertension.




Figure 1) Frequency of fibrinogen level among study group.




Figure 2) Positive correlation between PT result and age.




Figure 3) Positive correlation between APTT result and age.

DISCUSSION

Diabetes Mellitus (DM) is metabolic diseases characterized by hyperglycaemia resulting from defects in insulin secretion, insulin action, or both. The incidence of cardiovascular disease due to thrombosis is 2-4 folds greater in diabetic patients. Prothrombin time, activated partial thromboplastin time and platelet count are hematological indices that give an insight into the coagulation status [6]. This study aimed to Evaluation of PT and APTT in Diabetes Mellitus in Khartoum State. In the present study there is insignificant association between PT and management, hypertension, treatment and gender p-value (0.193, 0.55, 0.20 and 0.49) respectively. These finding strongly agreed with the results of a study in Sudanese diabetic patients by Abdulla et al. [7] which showed that PT was insignificant in patients of all duration of disease, also showed PT was insignificant in patients with different ages (p-value was 0.191) and PT had insignificant variation with in diabetic patients with and without treatment p. value was (0.178) also APTT insignificant with gender p. value was (0.905) and with treatment p. value was (0.267). This study finding showed that there was insignificant difference of APTT and management, hypertension, treatment and gender p-value (0.197, 0.34, 0.39, 0.21) respectively. This study similar agreed with many studies which done by Lippi and Mina [8,9]. The current study also showed that there was in significant difference of the mean PT, APTT within normal ranges. PT was (17 ± 3.8 sec) and APTT was (32.6 ± 4.1 sec). This similar to study done by Ambelu, et al. in Ethiopia showed that PTT was (32.8 ± 4.1 sec) [10]. Similarly, studies conducted in Iran by Soltani, et al. and in Nigeria by Ifeanyi, et al. reported in significant difference of PT findings among the groups. In this study the mean of fibrinogen level among

study participates was 136.3 mg/dl indicate to low level due to medications or lifestyle modifications this finding similar to shah,et al. [11,12].In this study the relation between plasma fibrinogen level and the age of diabetic type II patients there was in significant association (p = 0.329). In the present study the level of plasma fibrinogen among diabetic type II patients according to the gender was insignificant difference (p-value 0.594). This result was similar to study conducted in Sudan, that found the Fibrinogen level was significantly higher in diabetic type II patients, with no difference between males and females, p-value > 0.05 The current study was disagreement with studies that found plasma fibrinogen levels were higher among type 2 diabetes mellitus patients (656 mg/dl) as compared to controls (324 ± 139 mg/dl) which were statistically significant different p-value <0.01. This study was in not similar with other American study found that the mean plasma level of fibrinogen in the type II diabetics was higher than that of the normal population. This study was in agreement with study done by Noha, et al. which found the mean of D-dimer level among all patients was 2037 mg/ml. According to gender the males and females were showed 1859 mg/ml and 2295 mg/ml respectively. No significant correlations were found.

CONCLUSION

The present study show that shortened prothrombin time, activated partial thromboplastin time, shortened PT and APTT might be useful hemostatic markers in diabetic patients, especially in those at high risk for thrombotic complications. The Mean of plasma fibrinogen level in patient with type II diabetics mellitus were 136.3mg/dl, insignificant correlation with Fibrinogen levels with age, gender and duration of disease. The D. Dimer level show significant increase.

LIST OF ABBREVIATION

Term	Abbreviation
Diabetes mellitus	DM
Von Willebrand factor	VWf
Platelet Glycoprotein complexes I	Gp-1b
Tissue Factor	TF
High Molecular Weight	HMW
Prothrombin Time	PT
Statistical Package for Social Sciences	SPSS
Activated Partial Prothrombin Time	APTT
International Normalized Ratio	INR
Tissue Plasminogen Activator	TPA
Insulin Dependent Diabetes Mellitus	IDDM
Non-Insulin Dependent Diabetes Mellitus	NIDDM
Hemoglobin A1c	HA1C
Americans with Disabilities Act	ADA
Blood Urea Nitrogen	BUN
World Health Organization	WHO

ACKNOWLEDGEMENT

By the grace of Almighty Alla and his help I complete this study, all praise to him, my gratitude goes to Dr Enaam A, Rhman and Dr Khalid M, Khalid my supervisors whose guides me to complete this work, finally special thanks to patients who were so cooperative and despite their pain.

REFERENCES

1. Achneck HE, Sileshi B, Parikh A, et al. Pathophysiology of bleeding and clotting in the cardiac surgery patient: from vascular endothelium to circulatory assist device surface. *Circulation*. 2010;122:2068-2077.
2. Thornton P, Douglas J. Coagulation in pregnancy. *Best Practice and Research. Clinical Obstetrics and Gynaecology*. 2010;24:339-352.
3. Previtali E, Bucciarelli P, Passamonti SM, et al. Risk factors for venous and arterial thrombosis. *Blood Transfusion*. 2011;9:120.
4. McFarlane IA. Endocrine diseases and diabetes mellitus. In Williams JC, *Textbook of Diabetes*, Oxford: Blackwell. 1997;2ndEd:640-660.
5. Alvin CP. Diabetes. In: principles of internal medicine, Braunwald E, Fauci AS, kasper DL, Havser SL, Longo DL, Jambon JL: Harrison (eds), USA, New York, McGraw Hill. 2001;15thEd:2109-2138.
6. Bilous R, Donnelly R. *Handbook of diabetes*. John Wiley & Sons. 2010.
7. Abdulla AM, Elmissbah TE, Hamid EM, et al. *International journal of multidisciplinary and current research*. 2017.
8. Lippi G, Salvagno GL, Ippolito L, et al. Shortened activated partial thromboplastin time: causes and management. *Blood Coagulation and Fibrinolysis*. 2010;21:459-463.
9. Mina A, Favalaro EJ, Mohammed S, et al. A laboratory evaluation into the short activated partial thromboplastin time. *Blood Coagulation and Fibrinolysis*. 2010;21:152-157.
10. Ambelu YA, Shiferaw MB, Abebe M, et al. Prothrombin time, activated partial thromboplastin time and platelet counts of type II diabetes mellitus: a comparative study. *Journal of Diabetes and Metabolic Disorders*. 2018;17:117-121.
11. Mard-Soltani M, Dayer MR, Ataie G, et al. Coagulation factors evaluation in NIDDM patients. *American Journal of Biochemistry and Molecular Biology*. 2011;1:244-254.
12. Heemskerck JW, Bevers EM, Lindhout T et al. Changes in some coagulation parameters among diabetic patients in Michael Okpara university of agriculture, Umudike, Abia state, Nigeria. *World Journal of Pharmacy and Pharmaceutical Sciences*. 2014;3:52-61.